Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02611609 · ClinicalTrials.gov registry record · Phase 1
A Phase 1/2 Study to Assess MultiStem® Therapy in Acute Respiratory Distress Syndrome
A Phase 1 study of Acute Respiratory Distress Syndrome, sponsored by Healios K.K..
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 10
- Study locations
NCT02611609: Completed Phase 1 study of Acute Respiratory Distress Syndrome, sponsored by Healios K.K..
NCT02611609 is a Phase 1 study of Acute Respiratory Distress Syndrome that has completed, run by Healios K.K.. The registered enrollment target is 36 participants, below the 366-participant average among 31 other Acute Respiratory Distress Syndrome trials with a reported enrollment target (90% lower). The trial reports 10 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02611609, a Phase 1 study of Acute Respiratory Distress Syndrome, has completed, sponsored by Healios K.K..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 10
- Study locations
Study Summary
A study to examine the safety (and potential efficacy) of the adult stem cell investigational product, MultiStem, in adults who have Acute Respiratory Distress Syndrome (ARDS). The primary hypothesis is that MultiStem will be safe in ARDS patients.
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL MultiStem
Study Locations (10)
Other
- Queen Elizabeth Hospital - Birmingham
- Addenbrooke's Hospital - Cambridge
- University College London Hospital - London
- St. Georges Hospital - London
- Manchester Royal Infirmary - Manchester
- Wythenshawe Hospital - Manchester
- John Radcliffe Hospital - Oxford
Pennsylvania
- Hospital of the University of Pennsylvania - Philadelphia
- University of Pittsburgh Medical Center - Pittsburgh
Ohio
- University Hospitals - Cleveland Medical Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2016-01 |
| Est. Completion | 2019-07 |
| Phase | Phase 1 |
What the finished NCT02611609 record still lists
NCT02611609 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 366-participant average among 31 other Acute Respiratory Distress Syndrome trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Acute Respiratory Distress Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02611609 lists 10 locations in 3 states (Other, Pennsylvania, Ohio).
Frequently Asked Questions
What is clinical trial NCT02611609 about?
NCT02611609 is a clinical study titled "A Phase 1/2 Study to Assess MultiStem® Therapy in Acute Respiratory Distress Syndrome". A study to examine the safety (and potential efficacy) of the adult stem cell investigational product, MultiStem, in adults who have Acute Respiratory Distress Syndrome (ARDS). The primary hypothesis is that MultiStem will be safe in ARDS patients.
What is the current status of trial NCT02611609?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2016-01. Estimated completion is 2019-07.
What conditions does trial NCT02611609 study?
This clinical trial studies the following conditions: Acute Respiratory Distress Syndrome.
What interventions are being tested in trial NCT02611609?
The interventions under investigation include: Placebo (BIOLOGICAL), MultiStem (BIOLOGICAL).
Who is sponsoring clinical trial NCT02611609?
This trial is sponsored by Healios K.K., which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02611609 being conducted?
This trial has 10 study locations across Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Respiratory Distress Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02611609's enrollment target sits among peer trials
36 23rd of 31 higher than 9 of 31 other Acute Respiratory Distress Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acute Respiratory Distress Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety Study of Inhaled Carbon Monoxide to Treat Pneumonia and Sepsis-Induced Acute Respiratory Distress Syndrome (ARDS)
ACTIVE NOT RECRUITING · Phase 1
-
Effects of TNX-832 (Sunol cH36) in Subjects With Acute Lung Injury/Acute Respiratory Distress Syndrome
COMPLETED · Phase 1
-
Iloprost Effects on Gas Exchange and Pulmonary Mechanics
COMPLETED · Phase 1
-
A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19
COMPLETED · Phase 1
-
Human Mesenchymal Stem Cells For Acute Respiratory Distress Syndrome
COMPLETED · Phase 1
-
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia